FURAZANOBENZIMIDAZÓIS, ITS USE, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITION

专利摘要:
furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases. the present invention relates to a compound of formula (ii) wherein it represents a divalent benzene residue which is unsubstituted or substituted by one or two additional substituents independently selected from lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, alkoxy lower-lower alkyl, lower alkoxy-alkyl, phenyl, hydroxy, lower alkoxy, lower hydroxy-lower alkoxy, lower lower-alkoxy, lower phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, mono (lower alkyl) amino, di (lower alkyl) amino, mono (lower alkenyl) amino, di (lower alkenyl) amino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino in which the two substituents on nitrogen together with nitrogen form heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl 15, cyano, halogen , and nitro; or wherein two adjacent substituents can be methylenedioxy; or a divalent pyridine residue (z = n) which is unsubstituted or additionally substituted by lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, halo - lower alkyl 20, lower alkoxy-lower alkyl, or halogen; r1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; and r2 represents a group selected from: (b), (c) and (d) or pharmaceutically acceptable salts thereof.
公开号:BR112012001817B1
申请号:R112012001817-5
申请日:2010-07-26
公开日:2020-09-29
发明作者:Jens Pohlmann；Felix Bachmann
申请人:Basilea Pharmaceutica Ag；
IPC主号:

专利说明:

[0001] The present invention relates to substituted furazanobenzimidazole prodrugs, processes for preparing them and pharmaceutical compositions containing them, the use of them optionally in combination with one or more other pharmaceutically active compounds for the treatment of neoplastic diseases and autoimmune diseases.
[0002] Cancer is a major cause of death in humans. Although a wide variety of drugs against neoplastic diseases have already been developed and techniques such as surgery and radiotherapy are available, alternative and improved methods for the treatment of neoplastic diseases are still needed.
[0003] Autoimmune diseases are associated with abnormal lymphoproliferation as a result of defects in the termination of lymphocyte activation and growth. Generally, such diseases are associated with inflammation such as rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, among others. The treatment of such diseases focuses on anti-inflammatory and immunosuppressive drugs, which in several cases have severe side effects. Hence the need for alternative drugs with a new mode of action with fewer side effects.
[0004] Apoptosis is a term used to describe a series of cellular events that occur causing programmed cell death. There are several apoptotic paths, some of which have already been characterized, while others have yet to be elucidated. If the balance between cell division and apoptosis is disturbed, life-threatening diseases including cancer, autoimmune disorders, neurodegenerative and cardiovascular diseases can occur.
[0005] In recent years it has become evident that programmed cell death (apoptosis) is as important for the health of a multicellular organism as cell division. With repeated cell division and differentiation during tissue development or repair, excess cells or even harmful cells are generated. To maintain tissue homeostasis, these cells need to be removed or eliminated. The delicate interaction between cell growth and apoptosis in an organism is reflected in the complex molecular balance that determines whether an individual cell will undergo division, interrupt in the cell cycle or participate in programmed cell death.
[0006] Deregulation of cell proliferation, or lack of appropriate cell death, has widely varying clinical implications. Numerous diseases associated with such dysregulation involve hyperproliferation, inflammation, remodeling and tissue repair. Family indications in this category include cancers, restenosis, neoplasm hyperplasia, angiogenesis, endometriosis, lymphoproliferative disorders, transplant-related pathologies (graft rejection), polyposis, loss of neural function in the case of tissue remodeling, among others. Such cells may lose normal regulatory control of cell division, and may also not experience appropriate cell death.
[0007] As apoptosis is inhibited or delayed in most types of proliferative neoplastic diseases, induction of apoptosis is an option for the treatment of cancer, especially in those types of cancer that show resistance to classic chemotherapy, radiation and immunotherapy (Apoptosis and Cancer Chemotherapy, Hickman & Dive, eds., Blackwell Publishing, 1999). Also in autoimmune diseases and pathologies and those related to transplantation compounds that induce apoptosis can be used to restore normal cell death processes and therefore can eradicate symptoms and possibly cure diseases. Other applications of compounds that induce apoptosis may be restenosis, that is, accumulation of vascular smooth muscle cells on the walls of arteries, and persistent infections caused by a failure to eradicate cells infected with bacteria and viruses. In addition, apoptosis can be induced or restored in epithelial cells, endothelial cells, muscle cells, and other cells that have lost contact with the extracellular matrix. These cells are potentially capable of colonizing other organs and therefore can develop in pathologies such as neoplasms, endometriosis, among others.
[0008] Document W02004 / 103994 describes furazanobenzimidazole compounds of formula (I)
where R, R1 to R6 and X have certain broadly defined meanings as inducers of apoptosis in cancer cells.
[0009] The reference further describes that these compounds can be administered in the form of prodrugs that are decomposed in the human or animal body to give the corresponding formula (I) compound and mentions that among other types of prodrugs the amides of natural amino acids, for example example amides formed from the acid function of the amino acid and suitable amino groups of the compound of formula (i), are suitable as prodrugs.
[00010] The solubility in water of furazanobenzimidazoles such as those exemplified in document W02004 / 103994 is generally low. This poses a problem for the preparation of pharmaceutical compositions, especially compositions for parenteral administration. The reference suggests only in very general lines the use of an aqueous solution of a water-soluble salt of the compounds of formula (I) for parenteral administration.
[00011] Selected amides derived from furazanobenzimidazoles of the formula (I) mentioned above, where R represents an aryl or heteroaryl group substituted by at least one amino group, and a natural amino acid selected from glycine (Gly), alanine (Ala ) and lysine (Lys) show significantly improved water solubility and are cleaved in vivo giving the parental aromatic or heteroaromatic amine, thereby acting as prodrugs. The increased water solubility simplifies the preparation of pharmaceutical compositions and reduces the need for solubility-enhancing excipients in relation to the parent drug. This is especially advantageous since these excipients can cause unwanted toxic effects (Excipient Toxicity and Safety; Weiner, Myra L .; Kotkoskie, Lois A .; Editors. (2000), Publisher: Dekker, New York, USA. formulation vehicles: implications for cancer chemotherapy; ten Tije, Albert J .; Verweij, Jaap; Loos, Walter J .; Sparreboom, Alex; Clinical Pharmacokinetics (2003), 42 (7), 665-685).
[00012] Specifically for the lysine-derived prodrug (Lys), an extremely increased solubility is observed in an especially wide pH range and even under only slightly acidic conditions. These specific properties of the solubility of the lysine derivative also at higher pH values offer particularly excellent flexibility in the preparation of pharmaceutically acceptable compositions. It has also been discovered in pharmacokinetic studies in mice, that amide-type prodrugs derived from glycine (Gly), alanine (Ala) and lysine (Lys) provide significantly higher animal exposure to the parent drug (expressed as AUC (area under the curve) ) than those derived from other natural amino acids. For example, AUC values are more than 50 percent higher than AUC values found after administration of amide-like prodrugs derived from very similar natural amino acids such as asparagine (Asn) , serine (Ser), glutamine (Gin) or arginine (Arg).
[00013] Additionally, it was found that the specific prodrug derived from Lys of Example 1 of this application is better tolerated, provides longer exposure of the tumors to the drug and has a higher efficacy in tumor models in animals at the maximum tolerated dose than the corresponding parental drug. These surprising effects also suggest a higher efficacy of this prodrug in the therapy of neoplastic diseases and autoimmune diseases.
[00014] In an in vitro whole blood assay, an amino acid amide derived from the amino group of the furazan ring is converted to the parent drug less efficiently than the corresponding derivative with the amino acid amide being a substituent for the R residue in the formula ( I) mentioned above. This shows that not all amides derived from an amino group of the compound of formula (I) and a natural amino acid are equally suitable as prodrugs.
[00015] Several other types of amine-like prodrugs are described in the literature (for example AL Simplicio, JM Clancy, JF Gilmer, Molecules 2008, 13, 519-546; Prodrugs: Challenges and Rewards, [in: Biotechnol .: Pharm. Aspects, 2007; 5 (Pt, 2)] VJ Stella, RT Borchardt, MJ Hageman, R. Oliyai, H. Maag, JW Tilley, Editors, USA. 2007, pages 102-131, Publisher: (Springer, New York, NY); J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jvinvinen, J. Savolainen, Nature Rev. Drug Discovery 2008, 7, 255- 270). However, not every potential drug is sufficiently converted to the parent drug in all cases, which is exemplified with an amidine and a sulfamate derivative of furazanobenzimidazoles, which does not give quantifiable plasma levels of the parent drug after administration in animal studies. . This further underscores the challenge of identifying suitable drugs for a given drug combining all the required properties.
[00016] The present invention therefore relates to compounds of formula (II)
Where
represents a divalent benzene residue that is unsubstituted or substituted by one or two additional substituents independently selected from lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy , hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkyl-carbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxy-carbonylamino, lower alkyl-carbonylamino, substituted amino where the two substituents in nitrogen together with nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; or where two adjacent substituents can be methylenedioxy; or a divalent pyridine residue (Z = N) which is unsubstituted or additionally substituted by lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, halo lower alkyl, lower alkoxy-lower alkyl, or halogen; R1 represents hydrogen, lower alkyl-carbonyl, hydroxy-lower alkyl or cyano-lower alkyl; and R2 represents a selected group of:
and pharmaceutically acceptable salts thereof.
[00017] The furazanobenzimidazoles of formula (II) are prodrugs with improved water solubility and are cleaved in vivo to give the corresponding parent drug of formula (l-ll):
where R1 and Z have the same meanings as in formula (II). The compounds are also cleaved in cell and whole blood assays.
[00018] Furazanobenzimidazoles of formula (II) therefore have the same medicinal uses as the corresponding parent drugs that are described in detail in document W02004 / 103994. In particular, the compounds of formula (II) selectively induce apoptosis in cancer cells and can be used for the treatment of autoimmune neoplastic diseases. The invention therefore also relates to compounds of formula (II) for use as medicaments. In addition, the invention relates to methods for the synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (II), to the use of compounds of formula (II) for the preparation of a pharmaceutical composition for the treatment of neoplastic diseases and autoimmune, and methods of treating neoplastic and autoimmune diseases using such compounds of formula (II) or pharmaceutical compositions containing them.
[00019] For the purposes of this application, the suffix "lower" denotes a radical having from 1 to a maximum of 7 inclusive, especially from 1 to a maximum of 4 including carbon atoms, the radicals in question being linear or branched with a single branch or with multiple branches.
[00020] When the plural form is used for compounds, salts, among others, it should be considered as indicating also a single compound, salt, among others.
[00021] Double connections in principle can have the E- or Z- configuration. The compounds of this invention can therefore exist as isomeric mixtures or simple isomers. If not specified, both isomeric forms are considered.
[00022] Any asymmetric carbon atom not indicated in formula (II) as having a specific configuration may be present in the (R) -, (S) - or (R, S) - configuration, preferably in the (R) - configuration or (S) -. The compounds therefore can be present as mixtures of isomers or as pure isomers, preferably as stereoisomers free of enantiomer.
[00023] The invention also relates to the possible tautomers of the compounds of formula (II).
[00024] Lower alkyl preferably has 1 to 4 carbon atoms and is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Preferably lower alkyl is methyl or ethyl.
[00025] Cycloalkyl preferably has 3 to 7 ring atoms, and can be unsubstituted or substituted, for example with lower alkyl or lower alkoxy. Cycloalkyl is, for example, cyclohexyl, cyclopentyl, or methylcyclopentyl.
[00026] Aryl means an aromatic monocyclic or bicyclic fused ring group with 5 to 10 carbon atoms, such as phenyl, 1-naphthyl or 2-naphthyl, or also a partially saturated bicyclic fused ring group comprising a phenyl group, such as indanyl, dihydro-naphthyl or tetrahydronaphthyl.
[00027] If
represents a divalent benzene residue and comprises other substituents, these are preferably lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, methylenedioxy, haloalkyl lower, lower alkoxy-lower alkyl or halogen, more preferably lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, methylenedioxy, halo-lower alkyl, lower alkoxy-lower alkyl or halogen.
[00028] The divalent benzene residue is preferably 1,4-phenylene.
[00029] Heteroaryl represents an aromatic group containing at least one heteroatom selected from nitrogen, oxygen and sulfur, and is monocyclic or bicyclic. Monocyclic heteroaryl includes 5- or 6-membered heteroaryl groups containing 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and sulfur. Bicyclic heteroaryl includes 9- or 10-membered fused ring heteroaryl groups. Examples of heteroaryl include pyrrolyl, thienyl, furyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, such as benzyl derivatives, or benzofuryl, quinolinyl, isoquinolinyl, quinazolinyl, or purinyl.
[00030] If
represents a divalent pyridine group and comprises other substituents, these are preferably lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, halo-lower alkyl, lower alkoxy-lower alkyl, or halogen, more preferably lower alkoxy, amino or halogen.
[00031] Preferably, the divalent pyridine group is a group of formula

[00032] Heterocyclyl preferably designates a saturated, partially saturated or unsaturated monocyclic or bicyclic ring containing 4-10 atoms comprising one, two or three heteroatoms selected from nitrogen, oxygen and sulfur, which, unless otherwise specified, may be attached to a carbon or nitrogen, where a ring nitrogen atom can be optionally substituted by a selected group of lower alkyl, amino-lower alkyl, aryl, aryl-lower alkyl and acyl, and a ring carbon atom can be optionally substituted by lower alkyl, amino-lower alkyl, aryl, aryl-lower alkyl, heteroaryl, lower alkoxy, hydroxy or oxo. Examples of heterocyclyl are pyrrolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, dioxolanil and tetrahydropyranyl.
[00033] Acyl means, for example, lower alkyl-carbonyl, cyclohexylcarbonyl, arylcarbonyl, aryl-lower alkyl-carbonyl, or heteroarylcarbonyl. Acyl is preferably lower alkylcarbonyl, in particular propionyl or acetyl.
[00034] Hydroxy-lower alkyl is preferably hydroxymethyl, 2-hydroxyethyl or 2-hydroxy-2-propyl.
[00035] Cyano-lower alkyl preferably designates cyanomethyl and cyanoethyl.
[00036] Halo-lower alkyl is preferably fluorine-lower alkyl, especially trifluoromethyl, 3,3,3-trifluorethyl or pentafluorethyl.
[00037] Halogen is fluorine, chlorine, bromine, or iodine.
[00038] Lower alkoxy is especially methoxy, ethoxy, isopropyloxy, or tert-butyloxy.
[00039] Salts are especially pharmaceutically acceptable salts. Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from the compounds of formula (II) with a basic nitrogen atom. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic acids, phosphonic acids, sulfonic acids or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic, pyelic acid, submeric acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxylic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methanesulfonic acid or ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 , 5-naphthylene disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecyl acid sulfuric, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
[00040] For the purpose of isolation or purification it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.
[00041] In view of the close relationship between the new compounds in the free form and those in the form of their salts, including the salts that can be used as intermediates, for example in the purification or identification of the new compounds, any reference made to the free compounds above and below are to be understood as indicating also the corresponding salts, where appropriate and convenient.
[00042] The compounds of formula (II) can be used in the same way as the corresponding parent drugs. The invention therefore also relates to the compounds of formula (II) defined above for use as medicaments, in particular for the treatment of a neoplastic disease, an autoimmune disease, a transplant related pathology and / or a degenerative disease, in particular for the treatment of a solid neoplastic disease.
[00043] The compounds of formula (II) according to the invention show therapeutic efficacy especially against neoplastic diseases and autoimmune diseases. In particular, the compounds of the invention are active against malignancies, for example epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell papillomas and carcinomas, adenomas and adenocarcinomas, cutaneous and adnexal neoplasms, mucoepidermoid neoplasms, cystic neoplasms , mucous and serous neoplasms, ductal, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized gonadal neoplasms, glomus paragangliomas and tumors, nevi and melanomas, soft tissue tumors and sarcomas, fibromatous neoplasms, myxomatous neoplasms lipomatous, myomatous neoplasms, complex stromal and mixed neoplasms, fibroepithelial neoplasms, synovial-like neoplasms, mesothelial neoplasms, germ cell neoplasms, trophoblastic neoplasms, mesonephromas, tumors in blood vessels, tumors in lymphatic vessels, bone neoplasms and bone tumors , giant cell tumors, various bone tumors, odontogenic tumors, gliomas, neuroepitheliomatous neoplasms, meningiomas, neural sheath tumors, granular cell tumors and soft tissue alveolar sarcomas, Hodgkin's and non-Hodgkin's lymphoma, other lympho-reticular neoplasms , plasma cell tumors, mast cell tumors, immunoproliferative diseases, leukemias, various myeloproliferative disorders, lymphoproliferative disorders and myelodysplastic syndromes.
[00044] In particular, a compound of formula (II) according to the invention shows therapeutic efficacy especially against solid neoplastic diseases, for example epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell papillomas and carcinomas, adenomas and adenocarcinomas, neoplasms of cutaneous and adnexal appendages, mucoepidermoid neoplasms, cystic neoplasms, mucinous and serous neoplasms, ductal, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized gonadal neoplasms, gland tumors and melanoma tumors , tumors and soft tissue sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous neoplasms, complex stromal and mixed neoplasms, fibroepithelial neoplasms, synovial-like neoplasms, mesothelial neoplasms, germ cell neoplasms, tumors, trophoblastic tumors blood vessels, tumors in the lymphatic vessels, bone and chondromatous neoplasms, giant cell tumors, diverse bone tumors, odontogenic tumors, gliomas, neuroepitheliomatous neoplasms, meningiomas, neural sheath tumors, granular cell tumors and soft tissue alveolar sarcomas.
[00045] The compounds of the invention are also active against autoimmune diseases, for example against systemic, discoid or subacute lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, CREST, progressive multiple sclerosis, mixed connective tissue disease (Sharp syndrome), Reiter, juvenile arthritis, cold agglutinin disease, essential mixed cryoglobulinemia, rheumatic fever, ankylosing spondylitis, chronic polyarthritis, myasthenia gravis, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, Guillan-Barré syndrome, auto-myolytic dermatomyositis, hemolytic myopathies , neutropenia, type I diabetes mellitus, thyroiditis (including Hashimoto's and Grave's disease), Addison's disease, polyglandular syndrome, pemphigus (common, foliate, sebaceous and vegetative), bullous and scar pemphigoid, gestational pemphigoid, acquired epidermolysis, disease by linear IgA, lichen sclerosis and atrophic, Duhr disease ing, psoriasis vulgaris, gout, generalized pustular psoriasis and localized pustular psoriasis, vitiligo, alopecia in areas, primary biliary cirrhosis, autoimmune hepatitis, all forms of glomerulonephritis, pulmonary hemorrhage (goodpasture syndrome), IgA nephropathy, pernicious anemia and gastritis autoimmune, inflammatory bowel diseases (including ulcerative colitis and Crohn's disease), Behcet's disease, Celic-Sprue disease, autoimmune uveitis, autoimmune myocarditis, granulomatous orchitis, aspermatogenesis without orchitis, idiopathic and secondary pulmonary fibrosis, inflammatory diseases with the possibility of autoimmune pathogenesis, such as gangrenous pyoderma, lichen red, sarcoidosis (including Löfgren's syndrome and cutaneous / subcutaneous type), annular granuloma, type I and type IV immune allergic reaction, bronchial asthma, pollen, atopic dermatitis, contact dermatitis and dermatitis airborne, large vessel vasculitis (giant cell and Takayasu arteritis), vasculitis of the middle vessels (polyarteritis nodosa, Kawasaki disease), vasculitis of the small vessels (Wegener's granulomatosis, Churg Strauss syndrome, microscopic polyangiitis, Henoch-Schoenlein purpura, essential cryoglobulinemic vasculitis, cutaneous leukoclastic angeitis) toxic (Stevens-Johnson syndrome, erythema multiforme), diseases caused by side effects of drugs, all forms of cutaneous, organ-specific and systemic effects due to forms of immune response type l-VI (Coombs classification), related pathologies with transplantation, such as graft versus host and host versus acute and chronic graft disease, involving all organs (skin, heart, kidney, bone marrow, eye, liver, spleen, lung, muscle, central and peripheral nervous system, connective tissue , bone, blood and lymphatic vessel, genito-urinary system, ear, cartilage primary and secondary lymphatic system including me bone marrow, lymph nodes, thymus, gastrointestinal tract, including oropharynx, esophagus, stomach, small intestine, colon, and rectum, including parts of the organs mentioned above down to the level of a single cell and substructures, for example stem cells).
[00046] A compound of formula (II) can be administered alone or in combination with one or more other therapeutic agents, a combination therapy possible in the form of fixed combinations, or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents. A compound of formula (II) can also or additionally be administered especially for tumor therapy in combination with chemotherapy, radiation therapy, immunotherapy, surgical intervention, or a combination thereof. Long-term therapy is also possible as it is an adjunct therapy in the context of other treatment strategies, as already described above. Other possible treatments are therapy to maintain the patient's condition after tumor regression or chemopreventive therapy, for example in patients at risk. Particularly preferred is the use of the compounds of formula (II) in combination with radiotherapy.
[00047] Therapeutic agents for possible combinations are especially one or more cytostatic or cytotoxic compounds, for example a chemotherapeutic agent or several agents selected from the group comprising indarubicin, cytarabine, interferon, hydroxyurea, bisulfan, or a polyamine biosynthesis inhibitor, a protein kinase inhibitor, especially serine / threonine kinase protein, such as protein kinase C, or protein tyrosine kinase, such as epidermal growth factor receptor tyrosine kinase, a cytokine, a negative growth regulator, such as TGF- β or IFN-β, an aromatase inhibitor, a classic cytostatic agent, an inhibitor of the interaction of an SH2 domain with a phosphorylated protein, a Bcl-2 inhibitor and modulators of members of the Bcl-2 family such as proteins with only type domains Bax, Bid, Bad, Bim, Nip3 and BH3.
[00048] A compound according to the invention is not only used for the control (prophylactic and preferably therapeutic) of humans, but also for the treatment of other warm-blooded animals, for example commercially useful animals, for example rodents , such as mice, rabbits or rats, or guinea pigs. Such a compound can also be used with a reference standard to allow comparison with other compounds. Brief description of the drawings
[00049] Figure 1 shows a comparison of the antitumor activity of the lysine prodrug according to Example 1 and the corresponding parental drug in colorectal cancer xenografts SW480 after intravenous application once a week.
[00050] Figure 2 shows a comparison of the antitumor activity of said compounds in colorectal cancer xenografts SW480 after intravenous application 3 times a week.
[00051] With the groups of preferred compounds of formula (II) mentioned below, it is possible to use sensibly the definitions of substituents given in the general definitions mentioned below, for example, to replace general definitions with more specific definitions or especially by definitions that are considered preferred.
[00052] A specific embodiment of the invention are compounds of formula (II) as such, that is, which are not in the form of a salt. We have found, namely, that it is not necessary to use the salt form to provide sufficient solubility of the compounds in aqueous media. This is particularly the case with the compound of formula (II) where R2 represents the group of formula

[00053] These compounds are already quite soluble in aqueous media having a pH between 6.5 and 5.
Preferred are the compounds of formula (II) where the group
represents 1,4-phenylene or a group of formula

[00055] Another preferred group of the compounds of formula (II) are those where R1 represents hydrogen or cyano-lower alkyl, in particular cyanoethyl.
[00056] Another especially preferred selection of compounds of formula (II) are compounds of formulas
especially the compounds of formulas

[00057] Most preferred is the compound having the formula
and pharmaceutically acceptable salts thereof, for example, a hydrochloride salt.
[00058] The compounds of the invention can be prepared by processes which are known to be, in particular, a process, in which a compound of formula (l-ll)
where R1 and Z have the definition given for formula (II) and where the group
it may be optionally further substituted by one or two additional substituents already defined above or a derivative of such a compound comprising functional groups in protected form, or a salt thereof is (1) acylated with an amino acid of formula (III)
where R10 is selected from hydrogen (Gly); methyl (Ala) and protected aminobutyl (Lys) and R11 is a suitable amino protecting group, and (2) all protecting groups in a protected derivative of the resulting compound are removed to give a compound of formula (II) and, if desired , (3) said compound of formula (II) is converted to a salt as already described above, or a salt of a compound of formula (II) is converted to the corresponding free formula (II) compound or other salt, and / or a mixture of isomeric compounds is separated into the individual isomers.
[00059] Acylation of a compound of formula (l-ll) with an amino acid of formula (III) is carried out in a manner known perse, usually in the presence of an appropriate polar or dipolar aprotic solvent, with cooling or heating as necessary, for example in a temperature range of approximately 80 ° C to approximately 150 ° C, more preferably less than 30 ° C to more 120 ° C, especially in a range of about 0 ° C to the reflux temperature of the solvent used . Optionally a suitable base is added, in particular an aromatic base such as pyridine or collidine or a tertiary amine type base such as triethylamine or diisopropylethylamine, or an inorganic basic salt, for example potassium or sodium carbonate.
[00060] Acylation can be carried out under conditions used for the formation of amides known per se in peptide chemistry, for example with activating agents for the carboxy group, such as carbodiimides such as N, N'-diethyl-, N, N'-dipropyl-, N, N'-diisopropyl-, N, N'- dicyclohexylcarbodiimide and N- (3-dimethylaminoisopropyl) hydrochloride -N'- ethylcarbodiimide (EDC), or with agents such as 1-hydroxybenzotriazole (HOBt), benzotriazole-1-yloxytris (dimethylamino) -phosphonium (BOP) hexafluorphosphate (BOP), O- (7-aza-benzotriazol-1-iI) -N, N, N ', N', N ', N' -tetramethyl-uronium (HATU), 2- (2-oxo-1- (2H) -pyridyl) -1,1,3,3-tetramethyluronium (TPTU) tetrafluorborate, optionally in the presence of suitable bases, catalysts or correagents. The carboxy group can also be activated as an acyl halide, preferably as an acyl chloride, for example by reaction with thionyl chloride or with oxalyl chloride, or as a symmetrical or asymmetric anhydride, for example by reaction with halogens such as chloroformate ethyl, optionally in the presence of suitable bases, catalysts or coreagents.
[00061] If one or more other functional groups, for example carboxy, hydroxy or amino, are or need to be protected in a compound of formula (l-ll) or (III), because they should not participate in the reaction, these are the same protecting groups that are generally applied in the synthesis of amides such as, in particular peptide compounds, cephalosporins, penicillins, derivatives of nucleic acids and sugars, which are known to those skilled in the art. Suitable protecting groups for amino groups are for example t-butyl carbamate, benzyl carbamate or 9-fluorenylmethyl carbamate.
[00062] Protecting groups may already be present in precursors and should protect functional groups of interest from unwanted side reactions, such as alkylations, acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. A characteristic of the protecting groups is that they lend themselves easily, that is, without unwanted side reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzymatic activity, for example under conditions analogous to physiological conditions, and that they are not present in the final products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and below.
[00063] The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in traditional reference works for the synthesis of peptides and in special works on protecting groups such as JFW McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in "Methoden der organischen Chemie", Houben-Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, and TW Greene, GM Wuts "Protective Groups in Organic Synthesis", Wiley, New York, 2006.
[00064] In the additional procedural steps, carried out as desired, the functional groups of the starting compounds which are not to participate in the reaction may be present in the unprotected form or may be protected for example by one or more of the protecting groups mentioned above as "protecting groups" ". The protecting groups are then totally or partially removed according to one of the methods described there.
[00065] Salts of a compound of formula (II) with a salt-forming group can be prepared in a manner known per se. Acid addition salts of the compounds of formula (II) can therefore be obtained by treatment with an acid or a suitable anion exchange reagent.
[00066] Salts can generally be converted to free compounds, for example to acid addition salts by treatment with suitable basic agents, for example with alkali metal carbonates, alkali metal acid carbonates, alkali metal hydroxides, typically carbonate potassium or sodium hydroxide.
[00067] It should be emphasized that reactions analogous to the conversions mentioned in this chapter can also occur at the level of appropriate intermediaries.
[00068] All the procedural steps described in this report can be carried out under known reaction conditions, preferably under the conditions specifically mentioned, in the absence or generally in the presence of solvents or diluents, preferably which are inert to the reagents used and capable of dissolving them , in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in H + form, depending on the type of reaction and / or reactants at reduced, normal, or elevated temperature, for example example in the range of (minus 100) ° C to about 190 ° C, preferably from about (minus 80) ° C to about 150 ° C, for example at (minus 80) to 60 ° C, at (minus 20) up to 40 ° C, at room temperature, or at the boiling point of the solvent used, at atmospheric pressure or in a closed container, where appropriate under pressure, and / or in an inert atmosphere, for example, in an argon atmosphere or nitrog enium.
[00069] Salts can be present in all starting and transient compounds, if they contain salt-forming groups. Salts can also be present during the reaction of such compounds, as long as the reaction is not disturbed by them.
[00070] At all stages of the reaction, the isomeric mixtures that occur can be separated into their individual isomers, for example diastereomers or enantiomers, or in any mixtures of isomers, for example racemates or diastereomeric mixtures.
[00071] In the preferred embodiment, the compounds of formula (II) are prepared according to or by analogy with the processes and process steps described in the Examples.
[00072] The compounds of formula (II), including their salts, can also be in the form of hydrates or solvates.
[00073] The starting materials of formula (l-ll) and (III) are known and either commercially available or can be synthesized by analogy or according to methods that are known in the literature. The production of the compounds of formula (l-ll) is described for example in document W02004 / 103994 and can be carried out for example according to the following general reaction scheme:

[00074] The compounds of formula (II) can also be produced in the manner shown for the corresponding lysine amide prodrugs in the following general reaction scheme, where "Cbz" means benzyloxycarbonyl:

[00075] This process can not only be used for the production of the compounds of the present formula (II) but can also be advantageously used for the production of amide prodrugs of compounds of the formula (I) defined in document W02004 / 103994 in general with any natural amino acid, for example the amide-like prodrugs of the compounds of formula (I-II) already defined above with said amino acids, that is, with glycine, alanine, arginine, asparagine, asparaginic acid, cysteine, glutamine, glutamine acid , histidine, isoleucine, leucine, lysine, metonine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine for example.
[00076] The invention therefore also relates to a process for the production of a compound of formula (ll-G):
or a salt thereof, comprising the steps of: (a) reacting a compound of formula
with an alpha-amino acid derivative of the formula:
in the presence of an activating agent and optionally in the presence of suitable bases, catalysts or co-reagents, preferably in the presence of O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU ) and 2,4,6-collidine to give the compound of formula:
(b) reacting the product of step (a) with a bromination agent such as bromine or cupric bromide, preferably cupric bromide, to give the compound bromine of formula:
(c) reacting said bromine compound obtained in step (b) with a compound of formula:
in the presence of a base, for example potassium carbonate, to give the compound of formula:
R1 (d) removing all protecting groups that are present from the "protected amino acid" group to give the compound of formula (ll-G) and optionally (e) converting said compound of formula (ll-g) into a salt of the same, in whose formulas R1 and
have one of the meanings described above, R2-G is a group of formula
"Amino acid" represents a residue derived from a natural alpha-amino acid by removing the carboxyl group from the alpha-carbon atom of said amino acid, and "Protected amino acid" means the same amino acid as "amino acid", primary amino groups and if necessary also others functional groups of said amino acid, however, being protected by a suitable protecting group. Suitable protecting groups are known to those skilled in the art and are described for example in "Protective Groups in Organic Synthesis." Third Edition by Theodora W. Greene & Peter GM Wuts. John Wiley & Sons, New York. 1999. xxi + 779 pages. 16 x 24 cm. ISBN 0-471-16019-9.
[00077] The present invention also relates to pharmaceutical compositions which comprise a compound of formula (II) as an active ingredient or component and which can be used especially as a medicine, in particular in the treatment of the diseases mentioned above.
[00078] Compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, or for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred. The compositions comprise the active ingredient, preferably together with a pharmaceutically acceptable carrier. The dosage of the principle depends on the disease to be treated and the species, its age, weight, and individual condition, individual pharmacokinetic data, and the mode of administration.
[00079] The invention also relates to pharmaceutical compositions for use in a method for the prophylactic control or especially for the therapeutic control of the human or animal body, in particular in a method of treating a neoplastic disease, an autoimmune disease, a pathology related to transplantation and / or a degenerative disease, especially those mentioned above.
[00080] The invention also relates to processes and the use of compounds of formula (II) for the preparation of pharmaceutical preparations comprising compounds of formula (II) or salts thereof as a pharmaceutically active component.
[00081] The present invention also relates to the use of the compounds of formula (II) in depot systems for the local distribution of drugs such as biodegradable polymers.
[00082] A pharmaceutical composition for the prophylactic control or especially for the therapeutic control of a neoplastic disease, an autoimmune disease, a transplant related pathology and / or a degenerative disease, of a warm-blooded animal, especially a human or a mammal requiring such treatment, comprising a compound of formula (II) as an active ingredient in an amount that is prophylactically or especially therapeutically active against said diseases, is also preferred.
[00083] The pharmaceutical compositions comprise from approximately 1% to approximately 95% of active ingredient. Preferably, single dose administration forms comprise from approximately 20% to approximately 90% of active ingredient and forms that are not preferably single-dose types comprise from approximately 5% to approximately 20% of active ingredient. Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, or capsules. Other dosage forms are, for example, ointments, creams, pastes, foams, tinctures, lipsticks, drops, sprays, dispersions etc. Examples are capsules containing from about 0.01 g to about 1.0 g of active ingredient.
[00084] The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.
[00085] Specific preference is given to the use of solutions of the active principle, especially aqueous solutions, in particular isotonic aqueous solutions which, for example in the case of lyophilized compositions comprising the active principle alone or together with a carrier, for example mannitol, can be used. reconstituted before use. The pharmaceutical compositions can be sterilized and / or can comprise excipients, for example preservatives, stabilizers, wetting agents and / or emulsifiers, solubilizers, salts to regulate osmotic pressure and / or buffers and are prepared in a manner known per se, for example conventional dissolution and lyophilization processes. Said solutions or suspensions may comprise viscosity-increasing agents, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatines, or also solubilizers, for example Tween 80® (polyoxyethylene (20) sorbitan mono-oleate).
[00086] The production of injectable preparations is usually carried out under sterile conditions, as well as its introduction, for example, into ampoules or vials, and the sealing of the containers.
[00087] Suitable vehicles are especially fillers, such as sugars, for example lactose, sucrose, mannitol or sorbitol, cellulosic preparations, and / or calcium phosphates, for example tricalcium phosphate or calcium acid phosphate, and also binders, such as starches , for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone, and / or, if desired, disintegrants, such as the starches mentioned above, and also carboxymethyl starch, cross-linked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol, or derivatives thereof.
[00088] Tablet cores can be presented with suitable coating, optionally enteric, by using, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or for the preparation of enteric coatings, solutions of suitable cellulosic preparations, such as acetyl cellulose phthalate or hydroxypropyl methyl cellulose phthalate. Dyes or pigments can be added to tablets or tablet coatings, for example for identification purposes or to indicate different doses of the active ingredient.
[00089] Pharmaceutical compositions for oral administration also include hard capsules consisting of gelatin, and also sealed soft capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules can contain the active ingredient in the form of granules, for example mixed with fillers, such as corn starch, binders, and / or glidants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquid excipients, such as fatty oils, liquid paraffin oil or polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example polyoxyethylene sorbitan fatty acid ester type, can also be added.
[00090] Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active principle and a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
[00091] For parenteral administration, aqueous solutions of an active ingredient in a water-soluble form, for example in the form of a water-soluble salt, or aqueous injectable suspensions containing viscosity-enhancing substances, for example sodium carboxymethylcellulose, sorbitol and / or dextran, and, if desired, stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilisate and be made into a solution before parenteral administration by the addition of suitable solvents.
[00092] Solutions such as those used, for example, for parenteral administration can also be employed as solutions for infusion.
[00093] Preferred condoms are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
[00094] The present invention also relates to a method for the treatment of a neoplastic disease, an autoimmune disease, a transplant related pathology and / or a degenerative disease, which comprises administering a compound of formula (II) or a salt pharmaceutically acceptable, where the radicals and symbols have the same meanings defined above for formula (II), in an amount effective against said disease, to a warm-blooded animal in need of such treatment. The compounds of formula (II) can be administered as such or especially in the form of pharmaceutical compositions, prophylactically or therapeutically, preferably in an amount effective against said diseases, to a warm-blooded animal, for example a human, in need of such treatment. In the case of an individual having a body weight of about 70 kg the daily dose administered ranges from approximately 0.01 g to approximately 5 g, preferably from approximately 0.05 g to approximately 1.5 g, of a compound of the present invention.
[00095] The present invention also relates especially to the use of a compound of formula (II), or a pharmaceutically acceptable salt thereof, especially a compound of formula (II) which is considered preferred, or a pharmaceutically acceptable salt thereof. , as such or in the form of a pharmaceutical formulation with at least one pharmaceutically acceptable carrier for the therapeutic and also prophylactic control of one or more of the above diseases, in particular a neoplastic disease, an autoimmune disease, a transplant related pathology and / or a degenerative disease.
[00096] The preferred dose quantity, composition, and preparation of pharmaceutical formulations (drugs) to be used in each case are described above.
[00097] The following examples serve to illustrate the invention without however limiting the scope of the invention. Examples
[00098] Abbreviations: Cbz = benzyloxycarbonyl, DIPEA = N, N-diisopropyl-N-ethylamine, DMAP = N, N-dimethylaminopyridine, DMF = N, N-dimethylformamide, DMSO = dimethyl sulfoxide, eq. = equivalent, ESI = electrospray ionization, HATU = O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate, THF = tetrahydrofuran.
[00099] All reagents and solvents are of commercial quality and are used without further purification unless otherwise indicated.
[000100] Reported temperatures are the temperatures of the external bath unless otherwise indicated.
[000101] Mass spectra (ESI-MS) are recorded on a Waters Micromass ZQ spectrometer, on a Varian 1200L Quadrupole MS spectrometer or on an Agileant 1100 LC / MSD spectrometer.
[000102] NMR spectra are obtained with a 400 MHz Bruker Advance spectrometer or with a 400 MHz Varian Mercury Plus spectrometer using DMSO-dθ, CDCh, acetone-de, CD3OD, D2O as solvent. The chemical shifts (d) are expressed in ppm. Example 1 (A) Synthesis of 3- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino) -propionitrile
Benzyl ester of (4-Acetyl-phenyl) -carbamic acid

[000103] To a stirred solution of 10 g of 4-aminoacetophenone (74 mmol, 1 eq.) In a mixture of 60 ml of water and 100 ml of dioxane at 0 ° C, 12.43 g of NaHCOs (148 mmol, 2 eq.) and 15.3 g of benzyl chloroformate (85 mmol, 1.15 eq., 95% purity). The mixture is stirred at room temperature for 4 h and then concentrated under reduced pressure to remove dioxane. The suspension is diluted with 70 ml of water and 150 ml of ethyl acetate. The phases are separated and the organic layer is washed with 2x 50 ml of brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give 19.5 g of the product as a solid.
[000104] MS (ESI +): 270 [M + H],
[000105] 1H NMR (400 MHz, DMSO-d6) ppm: 10.18 (s, 1H), 7.92- 7.89 (m, 2H), 7.61-7.58 (m, 2H), 7.46-7.33 (m, 5H), 5.18 (s, 2H), 2.51 (s, 3H). [4- (2-Bromo-acetyl) -phenyl] - carbamic acid benzyl ester

[000106] A mixture of 18.5 g of benzyl ester of (4-acetyl-phenyl) -carbamic acid (95%, 65.3 mmol, 1 eq.) And 30.7 g of CuEto (138 mmol, 2, 1 eq.) In 740 ml of ethanol is heated to reflux for 2 hours. After cooling to room temperature, the mixture is filtered and the residue is washed with 2000 ml of ethyl acetate. The acid filtrates (pH <1) combined with ethanol and ethyl acetate and brought to pH 5 by adding a 1 N aqueous solution of NaOH. Then 200 ml of water are added. The organic phase is separated, washed with 3x 200 ml of brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give 23.78 g of the crude product as a solid, which is used in the next step without further purification.
[000107] MS (ESI +): 348 + 350 [M + H],
[000108] 1H NMR (400 MHz, DMSO-d6) ppm: 10.26 (s, 1H), 8.00-7.90 (m, 2H), 7.65-7.59 (m, 2H), 7.46-7.34 (m, 5H), 5.19 (s, 2H), 4.84 (s, 2H). (1 H-Benzoimidazol-2-yl) -hydroxy-imino-acetonitrile

[000109] To a chilled, stirred solution of 10 g of 2-benzimidazolylacetonitrile (63.6 mmol, 1 eq.) In 50 ml of glacial acetic acid is added in drops a solution of 4.83 g of sodium nitrite (70 mmol, 1.1 eq.) dissolved in a minimum amount of water (10 ml). After the addition is complete, the reaction mixture is left stirring at room temperature for 1 hour. The precipitate formed in the course of the reaction is filtered and washed with 2x 20 ml of cold water and 2x 30 ml of diethyl ether to give 11.8 g of the product as a light yellow solid.
[000110] MS (ESI +): 187 [M + H],
[000111] 1H NMR (400MHz, DMSO-d6) ppm: 14.44 (broad, 1H), 13.15 (s, 1H), 7.80-7.20 (m, 4H). 4- (1H-Benzoimidazol-2-yl) -furazan-3-ylamine

[000112] To a cold, stirred solution of 13.2 g of hydroxylamine hydrochloride (190 mmol, 3 eq.) In 20 ml of water, 15.3 g of potassium hydroxide (27.2 mmol, 4.3 eq. .) are added slowly. Then 60 ml of diglin (diethylene glycol dimethyl ether) and 11.8 g of (1H-benzoimidazol-2-yl) -hydroxy-imino-acetonitrile (63.4 mmol, 1 eq.) Are added. The ice bath is removed and the reaction mixture is heated to reflux for 8 hours (bath temperature 170 ° C). After cooling to room temperature, the reaction mixture is filtered and the residue is washed with water to give the first crop of the desired product (6.2 g). The filtrate is treated with 150 ml of water. The resulting suspension is filtered and washed with water to give a second crop of the product (2.17 g). The two harvests are combined and used in the next step.
[000113] MS (ESI +): 202 [M + H],
[000114] 1H NMR (400MHz, DMSO-d6) ppm: 13.7 (wide, 1H), 7.78 (wide, 2H), 7.35-7.32 (m, 2H), 6.84 (s , 2H). 3- [4- (1H-Benzoimidazol-2-yl) -furazan-3-ylamino] - propionitrile

[000115] To a stirred and chilled solution of 18.2 g of 4- (1H-benzoimidazol-2-yl) -furazan-3-ylamine (90.5 mmol, 1 eq.) In 240 ml of pyridine is added 30 ml of a solution of sodium methoxide (30% in MeOH) (163 mmol, 1.8 eq.) and subsequently 6 ml of acrylonitrile (90.5 mmol, 1 eq.). The reaction mixture is stirred at room temperature overnight, before being concentrated under reduced pressure. The residue is suspended in 250 ml of water and extracted with 4x 400 ml of ethyl acetate. The combined organic layers are washed with 2x 500 ml of brine, dried over N32SO4, filtered and concentrated under reduced pressure. The crude product is dissolved in about 1000 ml of refluxing ethyl acetate. Then 1700 ml of n-hexane are added to the solution. The resulting cloudy mixture is left to stand at room temperature overnight and the precipitate formed is filtered to give 11.1 g of the product as a light yellow solid. The filtrate is concentrated to dryness under reduced pressure and the residue is suspended in 100 ml of a 1/1 mixture of n-hexane / ethyl acetate. The suspension is filtered to give 4.7 g of additional product.
[000116] MS (ESI +): 255 [M + H],
[000117] 1H NMR (400 MHz, DMSO-d6) ppm: 13.75 (wide, 1H), 7.81 (wide, 1H), 7.61 (wide, 1H), 7.37-7.34 ( m, 2H), 7.21 (t, 1H, J = 6 Hz), 3.68 (q, 2H, J = Q Hz), 2.94 (t, 2H, J = 6 Hz). [4- (2- {2- [4- (2-Cyano-ethylamino) - furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -carbamic acid benzyl ester

[000118] To a stirred solution of 11.1 g of 3- [4- (1H-benzoimidazol-2-yl) -furazan-3-ylamino] -propionitrile (95%, 41.5 mmol, 1 eq.) In 90 ml of N, N-dimethylformamide 7.84 g of potassium carbonate (56.8 mmol, 1.3 eq.) Are added, followed by 23.25 g of [4- (2-bromo- acetyl) -phenyl] -carbamic (75%, 50.1 mmol, 1.2 eq.). The reaction mixture is stirred for 4 hours at room temperature. Then 700 ml of water are added and the resulting suspension is extracted with 3x 800 ml of ethyl acetate. The combined organic layers are washed with water and brine, dried over Na2SO4, filtered and concentrated to give the crude product as a dark brown solid. This crude product is suspended in 150 ml of a 2/1 mixture of ethyl acetate / methanol. Filtration gives 12.63 g of the desired product as a light brown powder.
[000119] MS (ESI +): 522 [M + H],
[000120] 1H NMR (400 MHz, DMSO-d6) ppm: 10.33 (s, 1H), 8.09 (d, 2H, J = 9 Hz), 7.91-7.82 (m, 2H) , 7.71 (d, 2H, J = 9 Hz), 7.50-7.36 (m, 8H), 6.33 (s, 2H), 5.22 (s, 2H), 3.70- 3.65 (m, 2H), 2.95 (t, 2H, J = 6.5 Hz). 3- (4- {1- [2- (4-Amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino) -propionitrile

[000121] To a suspension of 6.4 g of benzylic acid ester [4- (2- {2- [4- (2-cyano-ethylamino) -furazan-3-yl] -benzoimidazol-1-yl} - acetyl) - phenyl] -carbamic (12.3 mmol, 1 eq.) in a mixture of 700 ml of ethyl acetate and 500 ml of methanol, 1.3 g of 10% palladium on carbon are added. The reaction mixture is stirred for 3 hours in an atmosphere of hydrogen (1atm) at room temperature. It is then filtered through celite and concentrated under reduced pressure to give the crude product as a light yellow solid, which is suspended in 60 ml of a 7/5 ethyl acetate / methanol mixture. Filtration gives 3.5 g of the desired product as an off-white solid. The filtrate is concentrated and the residue is treated in the manner described above with 5 ml of the 7/5 ethyl acetate / methanol mixture. Filtration gives 0.45 g of a second crop of the product.
[000122] MS (ESI +): 388 [M + H],
[000123] 1H NMR (400 MHz, DMSO-d6) ppm: 7.89-7.87 (m, 1H), 7.83-7.77 (m, 3H), 7.47 (t, 1H, J = 6 Hz), 7.42-7.38 (m, 2H), 6.67-6.65 (m, 2H), 6.28 (s, 2H), 6.19 (s, 2H), 3 , 70-3.66 (m, 2H), 2.95 (t, 2H, J = 6.5 Hz). (B) Preparation of S- acid [4- (2- {2- [4- (2-cyano-ethylamino) - furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -amide 2,6- diaminohexanoic Procedure I
S- {5-Benzyloxycarbonylamino-5- [4- (2- {2- [4- (2-cyano-ethylamino) -furazan-3-yl] -benzoimidazol-1-yl} - acetyl) - benzyl ester phenylcarbamoil] -pentyl} -carbámico
Method A
[000124] To a solution of 1.926 g N, N-di-ZL-lysine (4.65 mmol; 1.2 eq.) In 10 ml N, N-dimethylformamide dried at 0 ° C 0.862 g of 4- methylmorpholine (8.52 mmol; 0.937 ml; 2.2 eq.) and 0.572 g of ethyl chloroformate (5.27 mmol; 0.503 ml; 1.36 eq.) and the mixture is stirred at 0 ° C for 10 minutes. Then a 1.5 g solution of 3- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino ) - propionitrile (3.87 mmol; 1 eq.) in 10 ml of dry N, N-dimethylformamide is added and the mixture is stirred at room temperature overnight. Conversion is not complete, so an additional 0.385 g of N, N-di-ZL-lysine (0.93 mmol; 0.24 eq.) In a small amount of N, N-dimethylformamide and 0.172 g of 4- methylmorpholine (1.7 mmol; 0.187 ml; 0.44 eq.) and 0.114 g of ethyl chloroformate (1.05 mmol; 0.1 ml; 0.27 eq.) are added and the reaction mixture is left overnight at room temperature. Then the reaction mixture is diluted with ethyl acetate and washed with a 5% citric acid solution and brine. The organic layer is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue is washed with a mixture of dichloromethane and diisopropyl ether and dried under reduced pressure to give 2.38 g of the product as an off-white solid.
[000125] MS (ESI +): 784.5 [M + H],
[000126] 1H-NMR (DMSO-d6) ppm: 10.5 (s, 1H), 8.12 (d, J = 8.8 Hz, 2H), 7.91-7.84 (m, 4H) , 7.66 (d, J = 7.5 Hz, 1H), 7.48-7.26 (m, 14H), 6.35 (s, 2H), 5.06 (s, 2H), 5, 00 (s, 2H), 4.21 - 4.15 (m, 1H), 3.69 (q, J = 6.5 Hz, 2H), 3.01-2.94 (m, 4H), 1 , 80-1.65 (m, 2H), 1.50-1.25 (m, 4H). Method B
[000127] 3.73 g of N, N-di-ZL-lysine (9.0 mmol; 1.2 eq.), 1.82 g of 2,3,5-collidine (15 mmol; 1.95 ml ; 2 eq.) And 5.7 g of HATU (15 mmol; 2 eq.) Are dissolved in 50 ml of dry N, N-dimethylformamide and the mixture is stirred at room temperature for 5 minutes. Then a solution of 2.9 g of 3- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino ) -propionitrile (7.5 mmol; 1 eq.) in 30 ml of dry N, N-dimethylformamide is added and the mixture is stirred at room temperature for 2 days. An additional 0.37 g of N, N-di-Z-L-lysine (0.9 mmol; 0.12 eq.) Is added and the mixture is stirred for one day at room temperature. Plus 0.74 g of N, N-di-ZL-lysine (1.8 mmol; 0.24 eq.), 0.36 g of 2.3.5-collidine (3 mmol; 0.39 ml; 0 , 4 eq.) And 1.14 g of HATU (3 mmol; 0.4 eq.) Are added and the reaction mixture is stirred for one day at room temperature.
[000128] Then the reaction mixture is diluted with ethyl acetate and washed with water, a 5% citric acid solution and brine. The organic layer is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue is washed with a mixture of cyclohexane / dichloromethane / ethyl acetate 1/2/2 and subsequently with a mixture of dichloromethane / diisopropyl ether 1/1. It is then dried under reduced pressure to give 4.26 g of the product as an off-white solid. S-2,6-diamino acid [4- (2- {2- [4- (2-cyano-ethylamino) -furazan-3-yl] - benzoimidazol-1-yl} -acetyl) -phenyl] -amide - hexanoic and its hydrochloride salt (Example 1)

[000129] A 4.77g solution of S- {5-benzyloxycarbonylamino-5- [4- (2- {2- [4- (2-cyano-ethylamino) -furazan-3-yl] - benzyl ester benzoimidazol-1 -yl} -acetyl) -phenylcarbamoyl] -pentyl} -carbamic (6.09 mmol; 1 eq.) in a mixture of 200 ml THF, 50 ml of methanol and 3.5 ml of 2 N hydrochloric acid treated with 0.129 g of Pd / C (10%) and the resulting mixture is stirred for 5 hours at room temperature in a hydrogen atmosphere (1 atm). Then the catalyst is removed by filtration and the solvents are removed under reduced pressure. The residue is purified by chromatography on MCI gel with water / acetonitrile 3/1 as eluent to give the desired product.
[000130] Conversion to the hydrochloride salt: The product is dissolved in a mixture of 50 ml of dioxane and 20 ml of methanol and the mixture is treated with 4 ml of a 4 M solution of HCI in dioxane. Then the solvents are removed under reduced pressure. The residue is washed with a mixture of dichloromethane and diisopropyl ether and dried under reduced pressure to give 1.59 g of the product as an off-white powder.
[000131] MS (ES +): 516.4 [M + H],
[000132] 1H-NMR (DMSO-d6) ppm: 11.6 (s, 1H), 8.51 (s, 3H), 8.16 (d, J = 8.3 Hz, 2H), 7.97 -7.85 (m, 7H), 7.45-7.39 (m, 3H), 6.36 (s, 2H), 4.19-4.17 (m, 1H), 3.69 (q , J = 6.3 Hz, 2H), 2.95 (t, J = 6.3 Hz, 2H), 2.81-2.79 (m, 2H), 1.99-1.88 (m, 2H), 1.65-1.61 (m, 2H), 1.50-1.46 (m, 2H). Procedure II
S- [5- (4-Acetyl-phenylcarbamoyl) -5-benzyloxycarbonylamino-pentyl] -carbamic acid benzyl ester

[000133] In a 250 ml flask equipped with a magnetic stirrer, 5.0 g of N, N'-dibenzyloxycarbonyl-L-lysine (12.06 mmol, 1.0 eq.), 9.17 g of HATU ( 24.13 mmol, 2.0 eq.) And 2.19 g of 2,4,6-collidine (18,10 mmol, 1.5 eq.) Are dissolved in 70 ml of N, N-dimethylformamide, and in then 1.96 g of 4-aminoacetophenone (14.48 mmol, 1.2 eq.) are added. The light yellow mixture is stirred at 10 ° C for 18 hours. The reaction mixture is diluted with 40 ml of a saturated aqueous solution of NH4 Cl. The white precipitate is filtered and the filtrate cake is washed vigorously with water and isopropyl ether to give 5.3 g of the desired product as a solid.
[000134] MS (ESI +): 532.3 [M + H],
[000135] 1H-NMR (400 MHz, DMSO-d6) ppm: 10.34 (s, 1H), 7.90 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8 , 8 Hz, 2H), 7.58 (m, 1H), 7.33-7.30 (m, 10H), 7.20 (m, 1H), 5.00 (s, 2H), 4.95 (s, 2H), 4.10 (m, 1H), 2.96 (m, 2H), 2.50 (s, 3H), 1.71-1.27 (m, 6H). S- {5-Benzyloxycarbonylamino-5- [4- (2-bromo-acetyl) -phenylcarbamoyl] -pentyl} -carbamic acid benzyl ester

[000136] In a 100 ml flask equipped with a magnetic stirrer, 0.5 g of S- [5- (4-acetyl-phenylcarbamoyl) -5-benzyloxycarbonylamino-pentyl] -carbamic acid benzyl ester (0.94 mmol , 1.0 eq.) Is dissolved in 15 ml of chloroform and 15 ml of ethyl acetate, and then 0.53 g of cupric bromide (2.35 mmol, 2.5 eq.) Is added to the flask. The dark green mixture is stirred at 78 ° C for 6 hours. The mixture is cooled to room temperature, diluted with 40 ml of dichloromethane and filtered. The filtrate is washed with 20 ml of water and the phases are separated. The aqueous phase is extracted twice with 10 ml of dichloromethane. The combined organic phases are washed with brine, dried over sodium sulfate and concentrated to give the crude product, which is purified by recrystallization from 3 ml of toluene to give 350 mg of the desired product as a light yellow solid.
[000137] 1H-NMR (400 MHz, DMSO-d6) ppm: 10.39 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8 , 0 Hz, 2H), 7.60 (m, 1H), 7.39-7.20 (m, 10H), 7.13 (m, 1H), 5.00 (s, 2H), 4.95 (s, 2H), 4.81 (s, 2H), 4.15 (m, 1H), 2.97 (m, 2H), 1.62-1.28 (m, 6H). S- {5-Benzyloxycarbonylamino-5- [4- (2- {2- [4- (2-cyano-ethylamino) -furazan-3-yl] -benzoimidazol-1-yl} - acetyl) benzyl ester - phenylcarbamoyl] -pentyl} -carbamic

[000138] In a 50 ml flask equipped with a magnetic stirrer, 1.3 g of S- {5-benzyloxycarbonylamino-5- [4- (2-bromo-acetyl) -phenylcarbamoyl] -pentyl} - benzyl ester carbamic (2.13 mmol, 1.0 eq.) and 569 mg of 3- [4- (1H-benzoimidazol-2-yl) -furazan-3-ylamino] -propionitrile (2.24 mmol, 1.05 eq .) are dissolved in 20 ml of N, N-dimethylformamide, and then 441 mg of potassium carbonate (3.19 mmol, 1.5 eq.) are added to the flask at room temperature. The mixture is stirred at room temperature for 30 minutes.
[000139] Then it is diluted with 20 ml of a saturated aqueous solution of NH4CI. The resulting precipitate is filtered and washed vigorously with water and methanol to give 1.3 g of the desired product as a light yellow solid.
[000140] The following compounds are prepared by analogy with the methods described above either as the free base or the hydrochloride salt:




Example 12 [(4- {2- [2- (4-Amino-furazan-3-yl) -benzoimidazol-1-yl] -acetyl} -phenylcarbamoyl) -methyl] -carbamic acid tert-butyl ester

[000141] To a stirred solution of 0.06 g of N-BOC-glycine (CAS 4530-20-5) (0.34 mmol; 1.2 eq.) In 1 ml of / V, / V'-dimethylformamide 0.16 g of 2- (7-aza-1H-benzotriazol-1-yl) -1,1,3,3-tetramethyluronium (0.43 mmol; 1.5 eq.) hexafluorophosphate and 0.1 ml of triethylamine (0.71 mmol; 2.5 eq.) at room temperature. After stirring for 0.5 hour at room temperature, a 0.1 g solution of 2- [2- (4-amino-furazan-3-yl) -benzoimidazol-1-yl] -1- (4-amino -phenyl) -ethanone (CAS 798577-83-0) (0.28 mmol; 1 eq.) in 1 ml of A /, A / '- dimethylformamide is added. The reaction solution is stirred overnight at room temperature. Then, a solution of 0.03 g of N-BOC-glycine (0.17 mmol; 0.6 eq.) Containing 0.08 g of 2- (7-aza-1H-benzotriazol-1-yl hexafluorphosphate ) -1,1,3,3-tetramethyluronium (HATU) (0.22 mmol; 0.75 eq.) And 0.05 ml of triethylamine (0.35 mmol; 1.25 eq.) In 0.5 ml of N, N'-dimethylformamide is added to the reaction solution at room temperature. The same mixture is added again after an additional 24 hours and after an additional 8 hours. The reaction mixture is then further stirred for 64 hours (total reaction time 120 hours). The reaction mixture is diluted with ethyl acetate (10 ml) and then washed with water (10 ml), 10% aqueous citric acid solution (10 ml), brine (2x5 ml), dried over magnesium sulfate, filtered and concentrated to dryness to give the crude product.
[000142] The crude product is subjected to silica gel column chromatography (eluent: ethyl acetate / cyclohexane = 1/1 to 4/1). The material obtained is recrystallized from dichloromethane to give 0.085 g of the desired product as a white powder.
[000143] MS (ESI +): 492.4 [M + H],
[000144] 1H-NMR (DMSO-d6) ppm: 10.40 (s, 1H), 8.12 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 7.6 Hz , 2H), 7.82 (d, J = 8.8 Hz; 2H), 7.40 (m, 2H), 7.11 (t, J = 6.0 Hz), 7.00 (s, 2H ), 6.33 (s, 2H), 3.79 (d, J = 6 Hz, 2H), 1.41 (s, 9H). 2-Amino-N- (4- {2-r2- (4-amino-furazan-3-yl) -benzoimidazol-1-ill-acetyl} -phenyl) -acetamide hydrochloride salt

[000145] To a stirred solution of 0.045 g of [(4- {2- [2- (4-amino-furazan-3-yl) -benzoimidazol-1-yl] -acetyl} -acetyl} -phenylcarbamoyl acid ) -methyl] -carbamic (0.09 mmol; 1 eq.) in 0.5 ml of 1,4-dioxane are added in drops 0.11 ml of a solution of 4 M HCl in 1,4-dioxane (0 , 44 mmol; 5eq.) At room temperature. The reaction mixture is stirred for 2 hours at room temperature. Then, 5 ml of diisopropyl ether are added and the resulting suspension is filtered, washed with diisopropyl ether (2x2 ml) and dried under reduced pressure to give 0.04 g of crude material. The crude solid is subjected to MCI gel column chromatography eluting with a water / acetonitrile mixture (85/15 to 70/30) containing 0.05% HCl, to give 0.014 g of the desired product as an orange powder.
[000146] MS (ESI +): 392.4 [M + H],
[000147] 1H-NMR (DMSO-d6) ppm: 11.21 (s, 1H), 8.29 (br.s., 3H), 8.16 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H), 7.84 (m, 2H), 7.41 (m, 2H), 7.1-6.9 (m, 2H), 6.36 (s, 2H), 3.95 (m, 2H). Example 13 (Comparison) 4- [1 - (2-T rimethylsilanyl-ethoxymethyl) -1 H-benzoimidazol-2-yl] - furazan-3-ylamine

[000148] To a stirred suspension of 0.5 g of 4- (1 H-benzoimidazol-2-yl) -furazan-3-ylamine (CAS 332026-86-5) (2.49 mmol; 1.0 eq. ) in 15 ml of dry tetrahydrofuran cooled to 0 ° C, 0.075 g of sodium hydride (2.98 mmol; 1.2 eq.) are added little by little. After stirring for 10 minutes at 0-5 ° C, the resulting clear solution is treated with 0.54 ml of 2- (trimethylsilyl) ethoxymethyl chloride (2.91 mmol; 1.17 eq.). The reaction solution is stirred for 0.5 hour at 0-5 ° C and then diluted with 30 ml of ethyl acetate. The solution is washed with water (20 ml) and brine (20 ml), dried over magnesium sulfate, filtered and concentrated to dryness. The oily residue is triturated in diisopropyl ether (10 ml) and the solvent is removed under reduced pressure to give 0.78 g of the desired product as an off-white solid.
[000149] MS (ESI +): 332.4 [M + H],
[000150] 1H-NMR (DMSO-d6) ppm: 8.01 (m, 2H), 7.65-7.53 (m, 2H), 7.13 (s, 2H), 6.22 (s, 2H), 3.72 (t, J = 8.0 Hz, 2H), 0.96 (t, J = 8.0 H, 2H), 0.01 (s, 9H). Benzyl ({4- [1 - (2-Trimethylsilanyl-ethoxymethyl) -1H-benzoimidazol-2-yl] -furazan-3-ylcarbamoyl} -methyl) -carbamic acid

[000151] To a stirred suspension of 1.42 g of NZ-glycine (CAS 1138-80-3) (6.65 mmol; 2.9 eq.) In 4 ml of dichloromethane is added in drops 1.23 ml of 1-chloro-N, N-2-trimethyl-1-propenylamine (9.17 mmol; 4 eq.) At room temperature. The resulting clear solution is stirred for 1 hour and then concentrated to dryness to give the corresponding acid chloride as a colorless oil. In a sealed tube, a stirred 0.8 g solution of 4- [1- (2-trimethylsilanyl-ethoxymethyl) -1H-benzoimidazol-2-yl] -furazan-3-ylamine (2.29 mmol; 1.0 eq.) in 10 ml of tetrahydrofuran cooled to 0-5 ° C is treated little by little with 0.29 g of sodium hydride (11.5 mmol; 5 eq.) and then with a solution of acid chloride freshly prepared in 5 ml of tetrahydrofuran. At the end of the addition, the ice bath is removed and the tube is closed with a lid. The solution is heated to 70 ° C and stirred for 21 hours at this temperature. The reaction mixture is allowed to cool to room temperature and is then diluted with 40 ml of ethyl acetate. Water (30 ml) is added cautiously and the two layers are separated. The organic phase is washed with brine (2 x 20 ml), dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure to give the crude product. The crude product is purified by silica gel column chromatography (eluent: ethyl acetate / cyclohexane = 5/95 to 55/45) to give 0.57 g of the desired product as a white solid.
[000152] MS (ESI +): 523.4 [M + H],
[000153] 1H-NMR (DMSO-d6) ppm: 11.76 (s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.89 (d, J = 8.2 Hz , 2H), 7.78 (d, J = 8.2 Hz, 2H), 7.53-7.29 (m, 5H), 6.08 (s, 2H), 5.08 (s, 2H) , 4.02 (J = 5.6 Hz, 2H), 3.59 (t, J = 8.0 Hz, 2H), 0.84 (t, J = 8.0 Hz, 2H), 0.01 (s, 9H). {[4- (1H-Benzoimidazol-2-yl) - furazan-3-ylcarbamoyl] -methyl} -carbamic acid benzyl ester

[000154] 0.55 g of benzyl acid ({4- [1 - (2-trimethylsilanyl-ethoxymethyl) -1H-benzoimidazol-2-yl] -furazan-3-ylcarbamoyl} -methyl) - carbamic (1, 00 mmol; 1 eq.) Are added little by little to 2.75 ml of trifluoroacetic acid (35.3 mmol; 35 eq.) At room temperature. The solution is stirred for 1 hour and then concentrated to dryness under reduced pressure. The residue is dissolved in 3 ml of THF. Then, 2 ml of an 8% aqueous sodium carbonate solution is added. The resulting biphasic mixture is heated to 50 ° C and vigorously stirred for 1.5 hours. Then, the mixture is diluted with 10 ml of ethyl acetate and 5 ml of water and the organic layer is separated, washed with brine (5 ml), dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure to give 0.4 g of the desired product as a white solid.
[000155] MS (ESI +): 393.3 [M + H],
[000156] 1H-NMR (DMSO-d6) ppm: 11.65 (s, 1H), 8.26 (t, J = 6.0 Hz, 1H), 7.67 (d, J = 8.0 Hz , 2H), 7.38-7.30 (m, 7H), 5.10 (s, 2H), 4.04 (d, J = 6.0 Hz, 2H). [4- (2- {2- [4- (2- Benzyloxycarbonylamino-acetylamino) -furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -carbamic acid benzyl ester

[000157] To a stirred solution of 0.4 g of {[4- (1H-benzoimidazol-2-yl) -furazan-3-ylcarbamoyl] -methyl} -carbamic acid benzyl ester (0.97 mmol, 1 eq .) in 6 ml of / V, / V'-dimethylformamide 0.2 g of potassium carbonate (1.4 mmol; 1.45 eq.) are added at room temperature followed by the addition of 0.41 g of benzyl ester [4- (2-bromo-acetyl) -phenyl] -carbamic acid (CAS 157014-41-0) (1.16 mmol; 1.2 eq.). The reaction mixture is stirred for 2 hours at room temperature and then diluted with 20 ml of ethyl acetate. The solution is washed with water (2 x 10 ml) and brine (2 x 10 ml), dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The residue is then dissolved in hot ethyl acetate (2 ml) and the solution is placed in an ice bath. After 0.5 hour, the resulting suspension is filtered and the solid is washed with cold ethyl acetate (1 ml) to give 0.2 g of the desired product as a white powder.
[000158] MS (ESI +): 660.5 [M + H],
[000159] 1H-NMR (DMSO-d6) ppm: 11.80 (s, 1H), 10.35 (s, 1H), 8.34 (t, J = 4.6 Hz, 1H), 8.11 (d, J = 8.0 Hz, 2H), 7.80 (m, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.50-7.32 (m, 12H) , 6.38 (s, 2H), 5.23 (s, 2H), 5.12 (s, 2H), 4.06 (d, J = 4.6 Hz, 2H). Hydrochloride salt of 2-Amino-N- (4- {1- [2- (4-amino-phenyl) - 2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-yl) - acetamide

[000160] A mixture of 0.2 g of [4- (2- {2- [4- (2-benzyloxycarbonylamino-acetylamino) -furazan-3-yl] -benzoimidazol-1-yl} -acetyl benzyl ester ) -phenyl] -carbamic (0.29 mmol; 1 eq.) in 2 ml of tetrahydrofuran and 2 ml of methanol containing 0.19 ml of a solution of 4 M HCl in 1,4-dioxane (0.86 mmol; 3 eq.) and 0.046 g of 10% Pd / C (0.04 mmol; 0.14 eq.) is stirred for 7 hours in a hydrogen atmosphere at room temperature. Then the mixture is filtered and the filtrate is concentrated under reduced pressure. The residue is suspended in 2 ml of a mixture of dichloromethane / diisopropyl ether (1/1, v / v) and the suspension is filtered. The solid is washed with 2 ml of diisopropyl ether and dried under reduced pressure to give the crude product. The solid is purified by MCI gel column chromatography (eluent water / acetonitrile = 75/25 to 65/35, containing 0.1% HCl) to give 0.02 g of the desired product as a light brown powder.
[000161] MS (ESI +): 392.3 [M + H].
[000162] 1H-NMR (DMSO-de) ppm: 11.29 (s, 1H), 8.46 (br.s., 3H), 7.95-7.83 (m, 4H), 7.41 (m, 2H), 6.98 (d, J = 8.4 Hz, 2H), 6.22 (s, 2H), 4.23 (m, 2H). Example 14 (Comparison) N '- [4- (2- {2- [4- (2-Cyano-ethylamino) -furazan-3-yl] - benzoimidazol-1-yl} -acetyl) -phenyl] -N, N-dimethylformamidine

[000163] A solution of 0.05 ml N, N-diisopropylethylamine in 1 ml of N, N-dimethylformamide is slowly added to a solution of 116 mg (0.3 mmol) 3- (4- {1- [ 2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino) -propionitrile and 459 mg (0.3 mmol) of phosphorus oxychloride in 3 ml of N, N-dimethylformamide at - 10 ° C. After the addition, the mixture is allowed to warm to room temperature and stirred for three days. Then, a saturated aqueous solution of ammonium chloride is added and the reaction mixture is extracted with dichloromethane. A precipitate is formed in the dichloromethane phase. This precipitate is collected by filtration, washed with water and dichloromethane, and dried under reduced pressure. The residue is dissolved in acetonitrile and the solution is added to a 2 N solution of sodium hydroxide in water at 0 ° C. The resulting pH value is greater than 11. The mixture is stirred at room temperature for 1 hour. The formed precipitate is collected by filtration, washed with water and acetonitrile, and dried under reduced pressure to give 89 mg of the desired product.
[000164] MS (ESI +): 443.2 [M + H],
[000165] 1H-NMR (DMSO-d6) ppm: 8.00-7.97 (m, 3H), 7.91-7.83 (m, 2H), 7.49-7.38 (m, 3H ), 7.11 (d, J = 8.5 Hz, 2H), 6.32 (s, 2H), 3.69 (q, J = 6.5 Hz, 2H), 3.09 (s, 3H ), 2.99 (s, 3H), 2.95 (t, J = 6.5 Hz, 2H). Example 15 (Comparison) Sodium salt of [4- (2- {2- [4- (2-Cyano-ethylamino) - furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -sulfamic acid

[000166] 50 ml_ (0.75 mmol) of chlorosulfonic acid are added in drops to 603 ml_ (7.5 mmol) of pyridine with cooling in an ice / ethanol bath. After stirring the mixture for 1 hour, 116 mg (0.3 mmol) of 3- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] - 1 H-benzoimidazole-2 -il} -furazan-3-ylamino) -propionitrile dissolved in a small amount of pyridine are added and the mixture is stirred at room temperature overnight. A 1 N aqueous solution of sodium hydroxide is added until pH 10 is reached. Then, the mixture is concentrated under reduced pressure. The residue is treated with water and the solid product (143 mg) is obtained by centrifugation, followed by washing with water and drying under reduced pressure.
[000167] MS (ESI +): 468.1 [M + H],
[000168] 1H-NMR (DMSO-d6) ppm: 8.89 (s, 1H), 7.90-7.81 (m, 4H), 7.49-7.37 (m, 3H), 7, 15 (d, J = 8.5 Hz, 2H), 6.25 (s, 2H), 3.69 (q, J = 6.5 Hz, 2H), 2.95 (t, J = 6.5 Hz, 2H). Methods for testing the compounds of the invention Determination of kinetic solubility:
[000169] The compounds, presented as 20 mM or 10 mM stock solutions in 100% DMSO, are diluted 1:40 in an aqueous buffer until they reach a concentration of 0.5 mM or 0.25 mM, respectively, with residual DMSO 2.5%. The pH 6.5 buffer consists of 0.05 M 3- (N-morpholino) -2-hydroxypropanesulfonic acid (MOPSO) adjusted to the desired pH with NaOH. Buffers at pH 5 and pH 3 are prepared from commercially available concentrates (Titrisol®, Merck). The samples are then incubated at room temperature for 6 hours with gentle shaking followed by vacuum filtration through a MultiScreen DV plate (Durapore hydrophilic PVDF membrane, 0.65 pm pore size, Millipore). The filtrates are adjusted until they reach 20% acetonitrile and analyzed by UV spectroscopy to obtain the maximum absorption and the corresponding wavelength. The concentration of the compound in the filtrate is calculated based on the linear part of a standard curve constructed using 3 to 5 known concentrations of each sample in aqueous buffer supplemented with 20% acetonitrile.
[000170] All amino acid derived prodrugs have improved water solubility over the parent drug. The highest solubility is obtained at pH 3 for all prodrugs. At pH 5 and pH 6.5, the lysine prodrug has the highest solubility.

In vivo pharmacokinetic studies:
[000171] The compounds are evaluated in vivo after intravenous administration to male NMRI mice using the Vena saphena screening method.
[000172] A dose of 1 mg / kg of the compound is administered i.v. as a bolus (5 ml / kg). Serial blood samples (40 pL) are extracted after saphenous vein puncture and collected in a capillary tube coated with sodium heparin from two mice at a time in the pre-dose, and after 5 min, 15 min, 30 min, 45 min , 1 h, 2 h, 4 h, 6 h, 8 h and 24 h after intravenous administration.
[000173] Blood samples are weighed and the blood is quenched in 300 pl of STOP solution consisting of acetonitrile / water (80:20) and an internal standard.
[000174] Blood concentrations of the compound (prodrug) and its parent drug are determined by LC-MS / MS analysis with a limit of quantification of 4 to 40 ng / mL.
[000175] Calculation of the area under the curve (AUC)
[000176] The arithmetic mean of plasma / blood concentrations are calculated using BLQ (below the limit of quantification) - value of zero if necessary. AllCinf average iv The area under the blood concentration curve- [ng * h / mL] time for an average normalized iv application (1 mg / kg) from time zero to the time of the last sampling with a concentration above the limit of quantification. The average AUCinfiv is calculated according to the linear trapezoidal rule.
[000177] In one study mice are treated intravenously with prodrugs according to the invention, followed by determining the blood concentration of the drug. For comparison, similar amide-like prodrugs based on other natural amino acids are also tested.
[000178] The value of the AUC is a measure for the total exposure of animals to the drug.
[000179] We found that prodrugs derived from lysine, glycine and alanine give parental drug AUC values at least 50% higher than those comparative to the base of the most closely related natural amino acids in chemical terms. This extraordinary increase in exposure to the parent drug after administration of the prodrugs according to the invention is quite surprising and unexpected.

After intravenous administration of Example 14 and Example 15 to mice, no significant levels of the parent drug 3- (4- (142- (4-amino-phenyl) -2-oxo-ethyl-1 H-benzoimidazol-2-yl} - furazan-3-ylamino) -propionitrile is detected. Pharmacokinetic studies in mice with xenograft
[000180] Female CD-1 Nu / Nu mice implanted with the human colon carcinoma cell line SW480 are treated with either "Parental Drug", ie 3- (4- {1- [2- (4-amino -phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino) -propionitrile, or with "Example 1" that is, [4- (2- { 2- [4- (2-cyano-ethylamino) - furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -amide of S-2,6-diaminohexanoic acid, after size tumor reaches approximately 150 mm3 +/- 10%. Mice (33 per compound) are treated iv (5 mL / kg) once a week with 10 mg / kg of "Parental Drug" (vehicle: NMP 6.7%, Solute HS15 10%, Kolidonl2 8.3% in demineralized water) or 24.5 mg / kg of "Example 1" (vehicle: sodium acetate in saline solution qs pH 5) for 2 weeks. Due to> 10% body weight losses in some animals, application volumes are subsequently reduced to 4 mL / kg resulting in doses of 8 mg / kg of "Parental Drug" and 19.6 mg / kg of "Example 1" for another week.
[000181] After 4- application (4- week), three mice / samples from the groups treated with "Parental Drug" and "Example 1" are selected before and 5 min, 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 4 h, 6 h and 24 h after administration. Blood is collected by cardiac puncture in K3EDTA tubes kept on ice until they are centrifuged at 4 ° C. The plasma is stored at -20 ° C. At necropsy, the tumors are removed and weighed. Tumors are stored at -20 ° C. Plasma and tumor samples are analyzed by LC-MS / MS. The pharmacokinetic parameters are calculated using the WinNonLin 5.2 software. All results for 0 "Example 1" represent the free base. Results
[000182] The tumor distribution of "Parental Drug", administered either as such or in the form of "Example 1", is demonstrated. Tumor concentrations are detected in the first sample 5 minutes after administration. The tumor / plasma ratio is approximately 1. There is no accumulation in the tumors, when the concentration in the tumor equals the concentration in the plasma. However, after the administration of "Example 1", the exposure of tumors to "Parental Drug" and "Example 1" is almost twice as long (T1 / 2 half-life of 8.3 and 9.6 h) compared to exposure after drug administration (Ti / 2 of 5.4 h).
[000183] Pharmacokinetic parameters of "Parental Drug" in plasma and tumor tissue after iv administration of 8 mg / kg "Parental Drug" to mice with xenograft

[000184] Pharmacokinetic parameters of "Parental Drug" in plasma and tumor tissue after iv administration of 19.6 mg / kg of "Example 1" to mice with xenograft

[000185] Pharmacokinetic parameters of "Example 1" in plasma and tumor tissue after iv administration of 19.6 mg of "Example 1" to mice with xenograft
In vivo efficacy studies:
[000186] Mice carrying SW480 colorectal cancer grafts are used to test and compare the anticancer efficacy and tolerability of intravenous (iv) application of the prodrug according to Example 1 ([4- (2- {2 - [4- (2-cyano-ethylamino) -furazan-3-yl] -benzoimidazol-1-yl} -acetyl) -phenyl] -amide) of S-2,6-diaminohexanoic acid and "parent drug "(3- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazol-2-yl} -furazan-3-ylamino) -propionitrile) at the level of maximum tolerated dose (BAT). Before the experiment regarding efficacy, a determination of the BAT of each compound administered once a week is made in nude mice without tumor, of the same lineage. Administration of 24.5 mg / kg of prodrug and 10 mg / kg of parental drug, given as an i.v. bolus once a week, results in> 10% body weight loss in some animals in both groups. BATs in tumor-bearing mice are therefore determined to be 15 - 20% lower, resulting in doses of 21 mg / kg of prodrug and 8 mg / kg of parental drug. Human colorectal carcinoma cells (SW480) are injected subcutaneously (4 x 106 cells) into the back of atypical nude mice 4-8 weeks old. The volume of the tumors is determined from measurements with compass of the length (L) and width (I) of the tumor according to the formula (L x l2) / 2. The tumors are allowed to expand to a volume of 200 mm3 (± 10%) before starting treatment. The prodrug and parent drug are administered iv for 24 days, either once a week at 21 mg / kg and 8 mg / kg, respectively, or three times a week (d 1/4/7) at 7.1 mg / kg. kg and 2.7 mg / kg, respectively (both programs represent the same total dose per week). The tumor volume and body weight are monitored daily.
[000187] Using the administration program once a week (cf. Figure 1), the prodrug produces a final T / C (ratio between tumor volume in the treatment group vs. the control group) on the 24th day of 34% (p <0.001 vs. controls) versus 45% for parental drug (p <0.001 vs. controls). Using the administration program three times a week (cf. Figure 2), the prodrug produces a final T / C (24th day) of 26% (p <0.001 vs. control) versus 54% for the parental drug (p = 0.002 vs. control). The changes in body weight observed were very small in all treatment groups. However, one animal in the parental drug treatment group (treatment three times a week) died on the 10th day.
[000188] Administration of prodrug three times a week offers significantly better efficacy in the mouse model with cancer xenograft than a corresponding administration of the parental drug (p <0.05).
[000189] Figure 1 shows a graphical representation of changes in mean tumor volume during the treatment period when using the administration program in which the prodrug and parent drug are given once a week for 24 days at doses of 21 mg / kg and 8 mg / kg, respectively, with appropriate control vehicles (5 ml / kg) administered according to the same program. The data points represent the mean values +/- SEM (n = 7-8 animals, each animal was grafted with a tumor).
[000190] Figure 2 shows a graphical representation of the changes in the average volume of the tumor during the treatment period when using the administration program in which the prodrug and the parental drug are given three times a week (d 1/4/7 ) for 24 days at doses of 7.1 mg / kg and 2.7 mg / kg in 5 ml / kg, respectively, with appropriate control vehicles (5 ml / kg) administered according to the same program. Again, the data points represent the mean values +/- SEM (n = 7-8 animals, each animal was grafted with a tumor). Comparison of the conversion of prodrug to drug of the prodrug according to Example 12 (the present invention) and the prodrug according to Example 13 (comparison) in whole blood Procedure:
[000191] 495 pL of fresh heparinized rat blood is inoculated with 5 pL of a 1 mg / mL solution of the analyte (prodrug) in DMSO at 37 ° C. After t = 0, 5, 15, 30, 60 and 120 minutes, a blood sample is collected and precipitated. Therefore, for 50 pL of blood sample or inoculated blood sample, 150 pL of acetonitrile containing an internal standard are added. The samples are centrifuged and 20 µl of the supernatant is injected into the HPLC system to determine the concentration of the compound (prodrug and parental drug) by LC-MS / MS analysis.
[000192] For calibration, a standard curve is prepared with a compound concentration range of 10 to 10,000 ng / mL in fresh heparinized rat blood. Therefore, the blood is inoculated (2 pL of DMSO solution in 198 pL of fresh rat blood) and precipitated as unknown samples. Results:
[000193] The prodrug 2-amino-N- (4- {2- [2- (4-amino-furazan-3-yl) - benzoimidazol-1-yl] -acetyl} -phenyl) -acetamide according to the present invention (Example 12) is completely converted to its parent drug 2- [2- (4-amino-furazan-3-yl) -benzoimidazol-1-yl] -1- (4-amino-phenyl) -ethanone in blood after 120 minutes, whereas the conversion of the regioisomer of said prodrug 2-amino-N- (4- {1- [2- (4-amino-phenyl) -2-oxo-ethyl] -1H-benzoimidazole -2-yl} -furazan-3-yl) - acetamide (Example 13) is markedly lower (approximately 74% after 120 minutes).

权利要求:
Claims (21)
[0001]
1. Compound, characterized by the fact that it presents formula (II)
[0002]
2. A compound of formula (II) according to claim 1, characterized by the fact that it is not a salt.
[0003]
3. Compound according to claim 1 or 2, characterized by the fact that
[0004]
Compound according to any one of claims 1 to 3, characterized in that R1 represents hydrogen or cyano-lower alkyl.
[0005]
Compound according to any one of claims 1 to 5, characterized in that it is selected from the compounds of formulas
[0006]
A compound according to any one of claims 1 to 5, characterized in that R1 is cyanoethyl.
[0007]
7. Compound according to claim 5 or 6, characterized by the fact that it is selected from the compounds of formulas
[0008]
8. Compound according to claim 2, characterized by the fact that it presents the formula
[0009]
Compound according to claim 1, characterized in that it is a pharmaceutically acceptable salt of the compound of formula
[0010]
10. Process for the preparation of the compound of formula (II), as defined in any one of claims 1 to 9, characterized by the fact that it comprises the steps in which: (1) a compound of formula (l-ll)
[0011]
11. Process for the production of a compound of formula (ll-G):
[0012]
Process according to claim 11, characterized by the fact that "amino acid" represents lysine.
[0013]
Process according to claim 11, characterized in that it is for the production of the compounds as defined in any one of claims 1 to 9.
[0014]
Compound according to any one of claims 1 to 9, characterized in that it is for use as the medicine.
[0015]
A compound according to any one of claims 1 to 9, characterized in that it is for use as a medicine for the treatment of a neoplastic disease, an autoimmune disease, a transplant-related pathology and / or a degenerative disease.
[0016]
16. Compound according to claim 14 or 15, characterized in that it is for the treatment of a solid neoplastic disease.
[0017]
Pharmaceutical composition, characterized in that it comprises a compound of formula (II) or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 9, and an inert and pharmaceutically acceptable carrier.
[0018]
18. Pharmaceutical composition according to claim 17, characterized by the fact that it is an aqueous solution.
[0019]
19. Pharmaceutical composition according to claim 17, characterized by the fact that it is soluble in an aqueous vehicle.
[0020]
20. Composition according to claim 17, characterized in that it is made as a composition for parenteral administration.
[0021]
21. Use of a compound of formula (II) as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, characterized in that it is for the preparation of a pharmaceutical composition for the treatment of a neoplastic disease , an autoimmune disease, a transplant-related condition and / or a degenerative disease, in particular for the treatment of a solid neoplastic disease.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012001817B1|2020-09-29|FURAZANOBENZIMIDAZÓIS, ITS USE, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITION

---

ES2688815T3|2018-11-07|Novel histone deacetylase inhibitors

---

ES2660914T3|2018-03-26|6- | nicotinamide derivatives and their use as PHD inhibitors

---

ES2300775T3|2008-06-16|FURAZANOBENCIMIDAZOLES.

---

ES2338060T3|2010-05-03|ARILOXI AND ARILTOXIA-CETOPHENONE TYPE COMPONENTS FOR CANCER TREATMENT.

---

CA2553704C|2011-04-19|Substituted benzimidazoles and their use for inducing apoptosis

---

AU2005215829A1|2005-09-01|Viral polymerase inhibitors

---

BRPI0814958B1|2021-05-11|INDOL COMPOUNDS AND COMPOSITION

---

AU2014251442A1|2015-12-03|Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives

---

BR122020009045A2|2020-11-10|USE OF N- [6-CIS-216-DIMETHYLMORFOLIN-4-IL] PYRIDINE-3-IL] -2-METHYL-4- (TRIFLUORMETOX0 [111 | -BIPHENYL] -3-CARBOXAMIDE SALTS

---

CN107056755A|2017-08-18|Five-ring heterocycles amide-type WNT pathway inhibitors

---

JP2014532656A|2014-12-08|Compounds for inflammation and immune related applications

---

BR112020010534A2|2020-10-20|1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

---

CN110143948B|2021-05-14|CDK4/6 inhibitor, pharmaceutical composition, preparation method and application thereof

---

WO2016107541A1|2016-07-07|Pyrrole amide compound, preparation method therefor, and use thereof

---

KR100832750B1|2008-05-27|Composition for preventing or treating an ischemic disease containing n-phenylamide derivatives

---

Samotrueva et al.2016|Synthesis and Immunotropic Activity of Quinazolin-4 |-One Carbonyl Derivatives

---

CN114206868A|2022-03-18|3- | -pyridin-4-yl) -5- | -1,2, 4-oxadiazole derivatives as HDAC6 inhibitors

---

WO2016107542A1|2016-07-07|Pyrrole amide compound, preparation method therefor, and use thereof

---

AU2012202711A1|2012-05-31|Viral polymerase inhibitors

同族专利:

---

公开号 | 公开日

---

CA2767875A1|2011-02-03|

---

PT2459553E|2014-11-24|

---

WO2011012577A1|2011-02-03|

---

MX2012000611A|2012-01-27|

---

PL2459553T3|2015-03-31|

---

AU2010277688B2|2013-12-05|

---

EA021380B1|2015-06-30|

---

RS53679B1|2015-04-30|

---

SI2459553T1|2015-01-30|

---

DK2459553T3|2014-11-03|

---

UA106763C2|2014-10-10|

---

US20120264792A1|2012-10-18|

---

KR20120055571A|2012-05-31|

---

TWI457337B|2014-10-21|

---

IL217195A|2014-03-31|

---

HRP20141120T1|2015-01-30|

---

CN102471329A|2012-05-23|

---

TW201107318A|2011-03-01|

---

CY1115809T1|2017-01-25|

---

EA201200189A1|2012-08-30|

---

NZ597376A|2014-01-31|

---

BR112012001817B8|2021-05-25|

---

IL217195D0|2012-02-29|

---

EP2459553B1|2014-10-01|

---

ZA201200228B|2012-09-26|

---

CN102471329B|2014-11-05|

---

CA2767875C|2016-03-15|

---

MX336240B|2016-01-13|

---

EP2459553A1|2012-06-06|

---

JP2013500304A|2013-01-07|

---

BR112012001817A2|2016-03-15|

---

AU2010277688A1|2012-02-09|

---

HK1166316A1|2012-10-26|

---

US8802858B2|2014-08-12|

---

JP5576485B2|2014-08-20|

---

ES2524119T3|2014-12-04|

---

KR101758400B1|2017-07-14|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US6897208B2|2001-10-26|2005-05-24|Aventis Pharmaceuticals Inc.|Benzimidazoles|

---

ES2437391T3|2002-02-06|2014-01-10|Vertex Pharmaceuticals, Inc.|Heteroaryl compounds useful as GSK-3 inhibitors|

---

DE602004011515T2|2003-05-23|2009-01-29|Basilea Pharmaceutica Ag|FURAZANOBENZIMIDAZOLE|

---

US20070167505A1|2004-02-11|2007-07-19|Basilea Pharmaceutica Ag|Substituted benzimidazoles and their use for inducing apoptosis|EP2666015B1|2011-01-21|2016-12-28|Basilea Pharmaceutica AG|Use of stathmin as a biomarker of drug response to furazanobenzimidazoles|

---

JP6302673B2|2011-01-21|2018-03-28|バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ|Use of BUBR1 as a biomarker of drug response to flazanobenzimidazole|

---

WO2012098203A1|2011-01-21|2012-07-26|Basilea Pharmaceutica Ag|Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles|

---

ES2621413T3|2011-02-24|2017-07-04|Basilea Pharmaceutica Ag|Use of acetylated tubulin as a biomarker of the drug response to furazanobenzimidazoles|

---

EP2691533B1|2011-03-29|2017-04-05|Basilea Pharmaceutica AG|Use of phospho-akt as a biomarker of drug response|

---

US9558575B2|2012-02-28|2017-01-31|Blackberry Limited|Methods and devices for selecting objects in images|

---

ITRM20130248A1|2013-04-24|2014-10-25|Medivis S R L|FORMULATIONS OF RIBOFLAVINA FOR TRANSEPITELIAL CROSS-LINKING.|

---

WO2015173341A1|2014-05-13|2015-11-19|Basilea Pharmaceutica Ag|Dosage principle for anti-cancer furazanylbenzimidazoles|

---

EP3365680A1|2015-10-22|2018-08-29|Basilea Pharmaceutica International AG|Use of eb1 as a biomarker of drug response|

---

CA3058695A1|2017-04-26|2018-11-01|Basilea Pharmaceutica International AG|Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof|

---

US20200237730A1|2017-05-16|2020-07-30|Basilea Pharmaceutica International AG|Novel dosage principle for drugs useful for treating neoplastic diseases|

---

US20200390749A1|2017-11-20|2020-12-17|Basilea Pharmaceutica International AG|Pharmaceutical combinations for use in the treatment of neoplastic diseases|

---

US20220031670A1|2018-09-20|2022-02-03|Basilea Pharmaceutica International AG|Pharmaceutical combinations for use in the treatment of neoplastic diseases|

---

WO2021048135A1|2019-09-09|2021-03-18|Basilea Pharmaceutica International AG|Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases|

---

CN111454254A|2020-04-26|2020-07-28|云白药征武科技有限公司|Preparation and application of benzimidazole derivative with fluorine-containing substituent|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-05-28| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-08-27| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-05-12| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-09-29| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |

---

2021-05-25| B16C| Correction of notification of the grant|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP09166469|2009-07-27|

---

EP09166469.8|2009-07-27|

---

PCT/EP2010/060803|WO2011012577A1|2009-07-27|2010-07-26|Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases|

---